These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2663145)

  • 21. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease.
    Nelson MV; Berchou RC; LeWitt PA; Kareti D; Galloway MP
    Neurology; 1990 Jan; 40(1):70-4. PubMed ID: 2296385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
    Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
    J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
    Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
    J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA; Gilhus NE
    Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
    Hutton JT; Morris JL
    Neurology; 1992 Jan; 42(1 Suppl 1):51-6; discussion 57-60. PubMed ID: 1549202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease.
    Hutton JT; Albrecht JW; Román GC; Kopetzky MT
    Arch Neurol; 1988 Jan; 45(1):55-7. PubMed ID: 3276299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease: recent advances in therapy.
    Jankovic J
    South Med J; 1988 Aug; 81(8):1021-7. PubMed ID: 3043683
    [No Abstract]   [Full Text] [Related]  

  • 33. Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.
    Pahwa R; Lyons K; McGuire D; Dubinsky R; Hubble JP; Koller WC
    Neurology; 1996 Apr; 46(4):1059-62. PubMed ID: 8780091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 35. Medical treatment of Parkinson's disease.
    Ahlskog JE
    Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
    [No Abstract]   [Full Text] [Related]  

  • 36. Unforeseen beneficial effects of controlled-release levodopa-carbidopa (Sinemet CR).
    Makela EH; Cutlip WD
    J Neuropsychiatry Clin Neurosci; 1992; 4(2):234-5. PubMed ID: 1627988
    [No Abstract]   [Full Text] [Related]  

  • 37. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
    Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS
    Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steady plasma levodopa concentrations required for good clinical response to CR-4 in patients with 'on-off'.
    McHale DM; Sage JI; Sonsalla PK; Heikkila RE; Duvoisin RC
    Eur Neurol; 1990; 30(2):90-2. PubMed ID: 2340841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
    LeWitt PA
    Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.